Stage III bladder urothelial carcinoma ajcc V6 and V7
Clinical trials for Stage III bladder urothelial carcinoma ajcc V6 and V7 explained in plain language.
Never miss a new study
Get alerted when new Stage III bladder urothelial carcinoma ajcc V6 and V7 trials appear
Sign up with your email to follow new studies for Stage III bladder urothelial carcinoma ajcc V6 and V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy combo shows promise for bladder cancer patients unable to get chemo
Disease control OngoingThis early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…
Matched conditions: STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Sea sponge compound tested against bladder cancer in patients with poor kidney function
Disease control OngoingResearchers are studying eribulin mesylate, a chemotherapy drug, in people with urothelial cancer that has spread or cannot be removed by surgery, and who also have kidney problems. The trial has two parts: one to find the highest dose patients can tolerate, and another to see ho…
Matched conditions: STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Immunotherapy after bladder cancer surgery: could it keep the cancer away?
Disease control OngoingThis Phase 3 trial tests whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent bladder cancer from returning after surgery. About 739 patients with muscle-invasive or locally advanced urothelial cancer are randomly assigned to receive pembrolizumab or just be o…
Matched conditions: STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug targets genetic weakness in bladder cancer
Disease control OngoingThis phase 2 trial tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific genetic change (TSC1 or TSC2 mutation). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors and h…
Matched conditions: STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC